Pharmaceuticals, Biotechnology and Life Sciences
Swedish Medivir said Monday that positive data from the investigator-initiated study of remetinostat in basal cell carcinoma (BCC) patients has shown that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs.
BioSpecifics reported net income of $4.4 million for the first quarter 2019, compared to net income of $4.0 million, for the same period in 2018.
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.
GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.
Denali has reported net loss of $39.0 million in the first quarter 2019, compared with a net loss of $23.7 million same period last year.
@GileadSciences said Thursday its total revenues were $5.3 billion in 2019 compared to $5.1 billion in 2018, with net income of $2.0 billion compared to $1.5 billion in 2018.
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
Eli Lilly will present 19 scientific abstracts for headache preventive drug Emgality (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019.
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First
Patient Showing Positive Initial Treatment